IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
If you’re looking to outsource drug product development to a CDMO, you need a collaborative partner who will engage you deeply to understand the unique needs of your project.
From pre-formulation to commercial manufacturing and packaging, you can trust Cambrex to deliver your complex dosage forms with the perfect combination of technology, expertise, and collaboration.
At Cambrex, we offer a tried and trusted approach to technology transfer, for scale-up or when transitioning to a different facility.
We are equipped to take on projects at any size or scale, offering established pediatric formulation and development expertise and to-scale manufacturing capabilities.
Biopharma companies at all stages of development, rely on our expertise and broad capabilities to produce the clinical trial supply of drug products they need, when they need them.
We can support you, at any size or stage, with a range of primary and secondary packaging solutions.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
CDMOs take on material at many different stages of development, and the design of analytic methods must account for the starting conditions in each unique case. In this example, Cambrex adopted a drug substance that lacked available data from previous analytical studies or synthesis. Despite these barriers, they set out to develop analytical methods to support pre-clinical and future GMP production under tight timelines.
Because there was little known about the compound, the team designed methods to assess the starting material, intermediate material and API purity. Screening methods included pH, mobile phases, columns, gradients, and column temperature. Mass spectrometry was used to understand impurity formation so that it could be controlled in the API and starting materials.
IN this case study, we discuss how Cambrex carefully designed methods for this API to be suitable and phase appropriate for future GMP use.
Thank you for your interest in our content.
Join us to hear Prof. Jonathan Douxfils, CEO and Co-Founder of QUALIblood, as he explains the latest regulations in biobanking and their impact on clinical studies, what changes researchers may need to implement in their projects, and the potential challenges in complying with these new regulations.
Despite the evolving landscape, the success rate for drug candidates during early development continues to be low. However, when you understand the pitfalls that can impede early development, the associated risks can be effectively managed, ultimately driving your program and your organization toward long-term commercial success.
Listen to Dr. Mark Powell as he discusses forced degradation studies – summarizing scientific principles, industry best practice, and available guidance.